Entering text into the input field will update the search result below

NantKwest rises 21% on ImmunityBio merger deal

Dec. 21, 2020 6:24 AM ETImmunityBio, Inc. (IBRX) StockBy: SA News Team
  • NantKwest (NK), up 21% premarket, and privately-held ImmunityBio have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease.
  • Together, ImmunityBio and NantKwest will have a broad, clinical-stage

Recommended For You

More Trending News

About IBRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IBRX--
ImmunityBio, Inc.